Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon

Oregon's 2020 legalization of psilocybin therapy for depression in terminal illnesses like advanced cancer has faced significant implementation challenges. This review synthesizes empirical data on psilocybin therapy for cancer-related depression, evaluating benefits and adverse effects. It examines therapeutic strategies, dosing regimens, and barriers to responsible, equitable access, including ethical protocols, healthcare integration, statewide availability, legal ambiguities, and clinical standards. Using Oregon as a case study, the review underscores the need to address regulatory, logistical, and ethical obstacles to establish rigorous and equitable psilocybin care models.

Study at a glance

Abstract

Despite the legalization of psilocybin therapy for depression in terminal illnesses such as advanced cancer through Oregon’s Measure 109 in 2020, significant challenges have impeded its implementation. This review synthesizes the empirical data supporting the utilization of psilocybin therapy for addressing cancer-related depression, including an evaluation of its purported benefits and potential adverse effects. It provides a comprehensive examination of therapeutic strategies, dosing regimens, and barriers to ensuring responsible and equitable access. Salient issues explored include the development of ethical protocols, integration within healthcare systems, ensuring statewide availability, resolving legal ambiguities, and defining clinical standards. Oregon’s pioneering role serves as a case study, highlighting the necessity of addressing regulatory, logistical, and ethical obstacles to ensure the establishment of rigorous and equitable psilocybin care models.